synthetic DMARDs + biological DMARDs + glucocorticoid

This is a combination therapy regimen used primarily in the management of autoimmune diseases such as rheumatoid arthritis. It consists of: - Synthetic disease-modifying antirheumatic drugs (DMARDs), which are small molecule agents that broadly suppress immune system activity to slow or halt disease progression. - Biological DMARDs, which are protein-based therapies (often monoclonal antibodies or fusion proteins) that target specific components of the immune system, such as cytokines or cell surface molecules. - Glucocorticoids, which are steroid hormones with potent anti-inflammatory and immunosuppressive effects, often used for rapid symptom relief and as bridging therapy until DMARDs take effect. The combination is designed to maximize disease control by leveraging different mechanisms of action. Synthetic DMARDs provide broad immunosuppression; biologics offer targeted inhibition of key inflammatory pathways; glucocorticoids deliver fast symptomatic relief but are generally recommended for short-term use due to their side effect profile[3][4][5]. This regimen is commonly employed in moderate-to-severe cases where monotherapy has proven insufficient.